Roxane Scemla, Hayes B Gladstone
This review introduces a neuroaesthetic framework that unifies aesthetic, functional, and therapeutic applications of BTX-A in facial paralysis and emphasizes its multi-systemic complexity. With appropriate knowledge and understanding of facial nerve dysfunction, dermatologists and clinicians experienced with neuromodulators are well positioned to deliver comprehensive function-guided treatments across the spectrum of facial paralysis-related sequelae.
BACKGROUND: Facial paralysis (FP) produces functional deficits and facial asymmetry that may include neuromuscular discoordination with synkinesis, painful muscle contractions, disturbing facial spasms, and autonomic misdirection such as gustatory lacrimation. Although Botulinum toxin A (BTX-A) is widely used in dermatology for aesthetic indications, its therapeutic and functional role in facial paralysis is less commonly incorporated within a clinical unified framework.
OBJECTIVE: To propose a neuroaesthetic framework that integrates functional restoration, therapeutic relief, and correction of facial asymmetry using Botulinum toxin A (BTX-A) in the management of facial paralysis.
METHODS AND MATERIALS: A structured narrative review of PubMed Index literature was conducted to evaluate aesthetic and therapeutic applications of BTX-A and facial paralysis. Evidence was synthesized across domains of facial asymmetry, functional impairment, and neuromuscular dysregulation and organized into a clinically applicable neuroaesthetic framework for dermatologists and advanced clinicians to support a comprehensive approach.
RESULTS: The reviewed literature supports BTX-A as an effective modality for reducing hyperkinesis and improving facial symmetry. Therapeutic benefit is also demonstrated for synkinesis, painful contractions, hemifacial spasms, and gustatory lacrimation. When applied using a comprehensive, integrated neuroaesthetic strategy, BTX-A enables concurrent management of functional deficits and therapeutic symptoms alongside aesthetic correction.
CONCLUSIONS: This review introduces a neuroaesthetic framework that unifies aesthetic, functional, and therapeutic applications of BTX-A in facial paralysis and emphasizes its multi-systemic complexity. With appropriate knowledge and understanding of facial nerve dysfunction, dermatologists and clinicians experienced with neuromodulators are well positioned to deliver comprehensive function-guided treatments across the spectrum of facial paralysis-related sequelae.